• Events
    • PSYCH Symposium
    • Emerging Innovations
  • Report
    • Fourth Edition
    • Third Edition
  • News & Insights
  • Newsletter
  • About
  • Contact
  • All
  • Analysis
  • Expert Interviews
  • News
  • Uncategorized
May 10, 2022

EXCLUSIVE: Biomind Labs’ relocation to the UK

Biomind Labs At PSYCH Symposium Biomind Labs announced it was relocating from Toronto to Cambridge, recognising the opportunities in Europe’s

Read More
Biomind Labs
May 4, 2022

Negev Capital and Investing in Psychedelic Healthcare

Negev Capital With US$30 million under its management, Negev Capital is a fund focused on psychedelic drug development, with investments

Read More
Negev Capital
April 27, 2022

MindMed, MM-120 and Dynamic Drug Development

At the start of 2022, the FDA cleared MindMed’s Investigational New Drug (IND) application for MM-120, paving the way for

Read More
MM-120
April 6, 2022

Filament Health and naturally extracted psychedelic medicines

Psilocybin was first isolated in 1958 by Albert Hofmann and is one of the most researched psychedelic medicines, with over

Read More
March 16, 2022

DMT and Major Depressive Disorder

At the PSYCH Symposium on 11 May, industry leaders will connect and collaborate to expedite access to psychedelic-based healthcare across

Read More
Major Depressive Disorder Small Pharma
  • Events
    • PSYCH Symposium
    • Emerging Innovations
  • Report
    • Fourth Edition
    • Third Edition
  • News & Insights
  • Newsletter
  • About
  • Contact
Partner with us

PSYCH is a data and insights platform for the psychedelic healthcare industry.

  • LinkedIn
  • Twitter
  • YouTube

Quick Links

  • Events
    • PSYCH Symposium
    • Emerging Innovations
  • Report
    • Fourth Edition
    • Third Edition
  • News & Insights
  • Newsletter
  • About
  • Psych Capital Plc.

Contact

17 Hanover Square
London W1S 1BN
United Kingdom

[email protected]+44 203 838 7621

The Psychedelics Newsletter

Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.

    Subscribe to the Psychedelics Newsletter

    Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.







      Subscribe to the Psychedelics Newsletter

      Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.